German drugmaker Merck KGaA and American-based drug giant Pfizer recently initiated two new clinical trials involving the PD-L1 inhibitor known as avelumab. Read More »
Kimberly Bartholomew was recently named the new GRx Hawaii regional account executive by Guaranteed Returns. Read More »
Democrat and Republican Senators criticized pharmaceutical companies Wednesday that have drastically hiked up the prices of life-saving medicines. Read More »
The Center for American Progress (CAP) recently submitted a proposal to improve Medicare by offering transparency in drug costs while reducing costs for consumers. Read More »
Bristol-Myers Squibb Foundation marked World AIDS Day Tuesday with $3.5 million in grants for HIV programs in Africa. Read More »
Immune Pharmaceutical, Inc. expanded its leadership team last week with the addition of two new hires. Read More »
U.S.-based drugmaker Pfizer said this week it is tackling the rising costs of prescription medicines head on by expanding its patient assistance program so that more people can gain access to free medicines. Read More »
Bristol-Myers Squibb has entered into a deal to acquire all issued and outstanding capital stock of Cardioxyl Pharmaceuticals, Inc. Read More »
The U.S. Food and Drug Administration (FDA) has approved Bristol-Myers Squibb Company’s Opdivo (nivolumab) injection for the treatment of patients with metastatic, non-small cell lung cancer (NSCLC) with progression on or after platinum-based chemotherapy. Read More »
Merck KGaA, Darmstadt, Germany and Pfizer on Wednesday announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to avelumab, a treatment for metastatic Merkel cell carcinoma. Read More »
Pfizer Inc. recently announced that it has completed the acquisition of GlaxoSmithKline’s quadrivalent meningococcal ACWY vaccines Nimenrix and Mencevax. Read More »
Package of 15 medicines for chronic diseases will be sold for $1 per treatment per month Read More »
Bristol-Myers Squibb launched its WorkingTogetherforPatients.com website on Monday as part of its Global Patient Week celebration.The new website shares stories of inspiration and connects with patients who are at the core of Bristol-Myers Squibb's mission. Read More »
Democratic presidential hopeful Hillary Rodham Clinton said this week that she would target excessive profiteering and marketing costs in the pharmaceuticals industry by encouraging innovation and new treatments from drug companies, if she were elected. Read More »
In response to the price for one prescription drug increasing by 5,000 percent as its demand for treatment of a common parasite that attacks people with weakened immune systems has grown, some health experts who treat patients with AIDS and cancer have denounced the new cost to treat a condition could be life-threatening. Read More »
The Center for American Progress has put forward a proposal to make changes within Medicare aimed at helping users, including instituting consumer-friendly ratings of the benefits new drugs may have, limiting what patients must pay for new drugs and requiring pharmaceutical companies to disclose how much is actually spent on researching and bringing new drugs to market, the Associated Press said. Read More »
Lion Biotechnologies Inc. on Monday announced it has opened enrollment in a Phase 2 clinical trial of its lead product candidate, LN-144, for the treatment of refractory metastatic melanoma. Read More »
TG Therapeutics, Inc. announced Wednesday the start of a Phase 1/2 clinical study investigating the use of TGR-1202, TG Therapeutic’s oral PI3K delta inhibitor and TG-1101 (ublituximab), in patients with relapsed or refractory CLL. Read More »
Heat Biologics Inc. on Tuesday announced it enrolled the first patient in a Phase 1b clinical trial that examines the combination of its HS-110 therapeutic vaccine and the Bristol-Myers Squibb PD-1 inhibitor nivolumab (Opdivo) in non-small cell lung cancer. Read More »
Corbus Pharmaceuticals Holdings Inc. on Monday announced that patient enrollment has commenced in the Phase 2 clinical study of its investigational new drug, Resunab, designed for the treatment of diffuse cutaneous systemic sclerosis. Read More »
Alerts Sign-up
